{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:15:31Z","timestamp":1778634931851,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"crossref","award":["LGF22H160040"],"award-info":[{"award-number":["LGF22H160040"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2502704"],"award-info":[{"award-number":["2022YFC2502704"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15896-5","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:33:25Z","timestamp":1775036005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianai","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Maleki","family":"Goli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parnia","family":"Ghanad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"9","key":"15896_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358. https:\/\/doi.org\/10.1056\/NEJMra2027612.","journal-title":"N Engl J Med"},{"key":"15896_CR2","unstructured":"Institute NC. Cancer stat facts: NHL\u2014Diffuse large B\u2010cell lymphoma (DLBCL). 2020."},{"issue":"2","key":"15896_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ajh.27151","volume":"99","author":"D Al-Sarayfi","year":"2024","unstructured":"Al-Sarayfi D, Brink M, Chamuleau MED, et al. R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study. Am J Hematol. 2024;99(2):216\u201322. https:\/\/doi.org\/10.1002\/ajh.27151.","journal-title":"Am J Hematol"},{"issue":"4","key":"15896_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"issue":"7277","key":"15896_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88\u201392. https:\/\/doi.org\/10.1038\/nature08638.","journal-title":"Nature"},{"issue":"4","key":"15896_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.22.00597","volume":"41","author":"J Westin","year":"2023","unstructured":"Westin J, Davis RE, Feng L, et al. Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol. 2023;41(4):745\u201355. https:\/\/doi.org\/10.1200\/JCO.22.00597.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15896_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"issue":"33","key":"15896_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III aspen study. J Clin Oncol. 2023;JCO2202830. https:\/\/doi.org\/10.1200\/JCO.22.02830.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15896_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00277-023-05498-7","volume":"103","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu J, Li P, Xu Y, Xue H, Liu P. Zanubrutinib-lenalidomide-rituximab (ZR(2)) in unfit diffuse large B-cell lymphoma: efficient and tolerant. Ann Hematol. 2024;103(2):499\u2013510. https:\/\/doi.org\/10.1007\/s00277-023-05498-7.","journal-title":"Ann Hematol"},{"issue":"1","key":"15896_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00314-w","volume":"11","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhang X, Wei J, et al. Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center. Exp Hematol Oncol. 2022;11(1):57. https:\/\/doi.org\/10.1186\/s40164-022-00314-w.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"15896_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35697","volume":"131","author":"X Yin","year":"2025","unstructured":"Yin X, He Q, Liu D, et al. Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: a phase 2 clinical study. Cancer. 2025;131(1):e35697. https:\/\/doi.org\/10.1002\/cncr.35697.","journal-title":"Cancer"},{"issue":"5","key":"15896_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9.","journal-title":"Lancet Oncol"},{"issue":"27","key":"15896_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15896_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382. https:\/\/doi.org\/10.1182\/blood-2003-05-1545.","journal-title":"Blood"},{"issue":"5","key":"15896_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491\u20138. https:\/\/doi.org\/10.1038\/ng.806.","journal-title":"Nat Genet"},{"issue":"5","key":"15896_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","volume":"129","author":"MLG Janssen-Heijnen","year":"2005","unstructured":"Janssen-Heijnen MLG, Van Spronsen DJ, Lemmens VEPP, Houterman S, Verheij KDGW, Coebergh JWW. A population-based study of severity of comorbidity among patients with non-Hodgkin\u2019s lymphoma: prognostic impact independent of international prognostic index. Br J Haematol. 2005;129(5):597\u2013606. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05508.x.","journal-title":"Br J Haematol"},{"issue":"26","key":"15896_CR17","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.65.6520.","journal-title":"J Clin Oncol"},{"issue":"24","key":"15896_CR18","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622\u201332. https:\/\/doi.org\/10.1002\/cncr.31646.","journal-title":"Cancer"},{"issue":"3","key":"15896_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10147-015-0912-6","volume":"21","author":"F Iioka","year":"2016","unstructured":"Iioka F, Izumi K, Kamoda Y, Akasaka T, Ohno H. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. Int J Clin Oncol. 2016;21(3):498\u2013505. https:\/\/doi.org\/10.1007\/s10147-015-0912-6.","journal-title":"Int J Clin Oncol"},{"issue":"22","key":"15896_CR20","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058\u201366. https:\/\/doi.org\/10.1002\/cncr.26135.","journal-title":"Cancer"},{"issue":"12","key":"15896_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317\u201328. https:\/\/doi.org\/10.1200\/JCO.20.01366.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15896-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:55:49Z","timestamp":1778633749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15896-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15896"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15896-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective interventional study involving human participants was conducted in accordance with the ethical standards of the Institutional and National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University (Approval No. 35-fast, 2021). Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}